BR0108221A - Use of a selective alpha-2b-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation and method for treating or preventing an alpha-2b-adrenoceptor-mediated disease in a mammal - Google Patents
Use of a selective alpha-2b-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation and method for treating or preventing an alpha-2b-adrenoceptor-mediated disease in a mammalInfo
- Publication number
- BR0108221A BR0108221A BR0108221-3A BR0108221A BR0108221A BR 0108221 A BR0108221 A BR 0108221A BR 0108221 A BR0108221 A BR 0108221A BR 0108221 A BR0108221 A BR 0108221A
- Authority
- BR
- Brazil
- Prior art keywords
- adrenoceptor
- alpha
- mammal
- antagonist
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
"UTILIZAçãO DE UM ANTAGONISTA ALFA-2B-ADRENOCEPTOR SELETIVO PARA A MANUFATURA DE UM PREPARADO FARMACêUTICO E PROCESSO PARA O TRATAMENTO OU PREVENçãO DE UMA ENFERMIDADE MEDIADA PELO ALFA-2B-ADRENOCEPTOR EM UM MAMìFERO". A presente invenção refere-se ao uso de um antagonista alfa-2B-adrenoceptor seletivo para a manufatura de um preparado farmacêutico de utilidade para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2B-adrenoceptor em um mamífero. O referido antagonista é um composto selecionado a partir do grupo que consiste de compostos A, B, C, D e E expostos no Esquema I, ou um sal farmaceuticamente aceitável do referido composto. A presente invenção também se refere a um processo para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2B-adrenoceptor em um mamífero. O mencionado processo compreende administrar ao dito mamífero uma quantidade efetiva do dito antagonista alfa-2B-adrenoceptor seletivo."USE OF A SELECTIVE ALPHA-2B-ADRENOCEPTOR ANTAGONIST FOR MANUFACTURING A PHARMACEUTICAL PREPARATION AND PROCESS FOR THE TREATMENT OR PREVENTION OF AN ALPHA-2B-ADRENOCEPTOR MEDIATED". The present invention relates to the use of a selective alpha-2B-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of an alpha-2B-adrenoceptor-mediated disease in a mammal. Said antagonist is a compound selected from the group consisting of compounds A, B, C, D and E set forth in Scheme I, or a pharmaceutically acceptable salt of said compound. The present invention also relates to a process for treating or preventing an alpha-2B-adrenoceptor-mediated disease in a mammal. Said process comprises administering to said mammal an effective amount of said selective alpha-2B-adrenoceptor antagonist.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18202100P | 2000-02-11 | 2000-02-11 | |
| FI20000303A FI20000303A0 (en) | 2000-02-14 | 2000-02-14 | Compounds Useful for the Treatment or Prevention of Alpha-2B Adrenoceptor Mediated Disease |
| PCT/FI2001/000105 WO2001058454A1 (en) | 2000-02-11 | 2001-02-07 | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0108221A true BR0108221A (en) | 2003-03-05 |
Family
ID=26160944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0108221-3A BR0108221A (en) | 2000-02-11 | 2001-02-07 | Use of a selective alpha-2b-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation and method for treating or preventing an alpha-2b-adrenoceptor-mediated disease in a mammal |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1253926A1 (en) |
| JP (1) | JP2003522148A (en) |
| KR (1) | KR20020080413A (en) |
| AU (1) | AU780802B2 (en) |
| BR (1) | BR0108221A (en) |
| CA (1) | CA2399421A1 (en) |
| CZ (1) | CZ20022884A3 (en) |
| EA (1) | EA200200846A1 (en) |
| EE (1) | EE200200435A (en) |
| GE (1) | GEP20043356B (en) |
| HR (1) | HRP20020746A2 (en) |
| HU (1) | HUP0300032A3 (en) |
| IL (1) | IL151017A0 (en) |
| IS (1) | IS6476A (en) |
| MX (1) | MXPA02007454A (en) |
| MY (1) | MY133957A (en) |
| NO (1) | NO20023773D0 (en) |
| NZ (1) | NZ520500A (en) |
| PL (1) | PL357872A1 (en) |
| SK (1) | SK11472002A3 (en) |
| WO (1) | WO2001058454A1 (en) |
| YU (1) | YU59102A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000615A (en) * | 2001-07-20 | 2004-04-20 | Juvantia Pharma Ltd Oy | Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor. |
| FI116940B (en) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | New N-pyrimidinyl para-aminobenzenesulfonamide derivatives as Alpha-2B adrenoceptor antagonists, useful for treating e.g. coronary heart disease, myocardial infarction, angina, restenosis and hypertension |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416432D0 (en) * | 1984-06-28 | 1984-08-01 | Wyeth John & Brother Ltd | Benzoquinolizines |
| RU2086544C1 (en) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity |
| US6150389A (en) * | 1994-07-11 | 2000-11-21 | Allergan Sales, Inc. | Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents |
-
2001
- 2001-02-07 PL PL01357872A patent/PL357872A1/en not_active Application Discontinuation
- 2001-02-07 AU AU35510/01A patent/AU780802B2/en not_active Ceased
- 2001-02-07 CA CA002399421A patent/CA2399421A1/en not_active Abandoned
- 2001-02-07 JP JP2001557564A patent/JP2003522148A/en active Pending
- 2001-02-07 EP EP01907585A patent/EP1253926A1/en not_active Withdrawn
- 2001-02-07 WO PCT/FI2001/000105 patent/WO2001058454A1/en not_active Application Discontinuation
- 2001-02-07 YU YU59102A patent/YU59102A/en unknown
- 2001-02-07 IL IL15101701A patent/IL151017A0/en unknown
- 2001-02-07 MX MXPA02007454A patent/MXPA02007454A/en unknown
- 2001-02-07 CZ CZ20022884A patent/CZ20022884A3/en unknown
- 2001-02-07 HU HU0300032A patent/HUP0300032A3/en unknown
- 2001-02-07 BR BR0108221-3A patent/BR0108221A/en not_active IP Right Cessation
- 2001-02-07 EE EEP200200435A patent/EE200200435A/en unknown
- 2001-02-07 GE GE4893A patent/GEP20043356B/en unknown
- 2001-02-07 NZ NZ520500A patent/NZ520500A/en unknown
- 2001-02-07 KR KR1020027010329A patent/KR20020080413A/en not_active Application Discontinuation
- 2001-02-07 EA EA200200846A patent/EA200200846A1/en unknown
- 2001-02-07 SK SK1147-2002A patent/SK11472002A3/en unknown
- 2001-02-09 MY MYPI20010579A patent/MY133957A/en unknown
-
2002
- 2002-07-19 IS IS6476A patent/IS6476A/en unknown
- 2002-08-09 NO NO20023773A patent/NO20023773D0/en not_active Application Discontinuation
- 2002-09-11 HR HRP20020746 patent/HRP20020746A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001058454A1 (en) | 2001-08-16 |
| AU3551001A (en) | 2001-08-20 |
| IS6476A (en) | 2002-07-19 |
| EP1253926A1 (en) | 2002-11-06 |
| EE200200435A (en) | 2003-12-15 |
| HRP20020746A2 (en) | 2004-12-31 |
| NZ520500A (en) | 2005-01-28 |
| HUP0300032A2 (en) | 2003-05-28 |
| CA2399421A1 (en) | 2001-08-16 |
| SK11472002A3 (en) | 2003-02-04 |
| IL151017A0 (en) | 2003-02-12 |
| KR20020080413A (en) | 2002-10-23 |
| JP2003522148A (en) | 2003-07-22 |
| GEP20043356B (en) | 2004-04-13 |
| NO20023773L (en) | 2002-08-09 |
| PL357872A1 (en) | 2004-07-26 |
| MY133957A (en) | 2007-11-30 |
| EA200200846A1 (en) | 2002-12-26 |
| CZ20022884A3 (en) | 2003-02-12 |
| YU59102A (en) | 2005-11-28 |
| MXPA02007454A (en) | 2004-08-23 |
| NO20023773D0 (en) | 2002-08-09 |
| HUP0300032A3 (en) | 2006-01-30 |
| AU780802B2 (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214967A (en) | Compound, pharmaceutically acceptable salt, process for preparing a compound, pharmaceutical composition, use of a compound and method of treating a patient disorder | |
| BR0110420A (en) | Muscarinic Agonists | |
| BR0211119A (en) | Compound, method of treating a patient who has, or preventing a patient from catching, a disease or condition, use of a compound, and method for making a compound | |
| PT1326613E (en) | USE OF IMIDAZO [1,2-A] PYRIDIN-, IMIDAZO [1,2-A] PYRIMIDIN- AND IMIDAZO [1,2-A] PYRAZIN-3-IL-AMINE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES FOR INHIBITION OF WE | |
| BR0012136A (en) | Highly selective norepinephrine reabsorption inhibitors and methods of using them | |
| BR0115382A (en) | Controlled release formulations of hydrocodone, method of producing effective analgesia, process of preparing a pharmaceutical form of a controlled release oral solid, controlled release of the oral dosage form and use of the pharmaceutical form | |
| BR0210122A (en) | Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same | |
| BR0313743A (en) | Benzimidazole quinolinones and uses of these | |
| BR0307441A (en) | Compounds, process for preparing a compound, pharmaceutical composition, use of such compounds, method for treating and prophylaxis of diseases and method for treating obesity | |
| BR0317717A (en) | Compound, pharmaceutical composition, use of a compound, method for treating a human suffering from a disease, and process for the preparation of a compound | |
| EP1095656A3 (en) | Pharmaceutical preparation comprising Galanthamine as cholinesterase inhibitor | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| BR0317680A (en) | Compound, pharmaceutical composition, use of a compound, or a pharmaceutically acceptable salt thereof, method of treating a human, and process for preparing a compound | |
| ATE415410T1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND OTHER SKIN DISEASES | |
| BR0316458A (en) | Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound | |
| BR0308108A (en) | Compounds; process for the preparation of compound; pharmaceutical composition comprising the same, use of compounds and method of treatment and prophylaxis of diseases and obesity | |
| BR0313278A (en) | Compounds, process for the preparation of a compound, pharmaceutical composition comprising the same and its use, method for treating and prophylaxis of diseases and obesity and use of the compounds | |
| WO2003000173A3 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
| BR0211030A (en) | Pyrrolidine oxadiazole derivative, use of a pyrrolidine oxadiazole derivative, pharmaceutical composition containing at least one pyrrolidine oxadiazole derivative, method for preparing a pyrrolidine oxadiazole compound | |
| BR0108221A (en) | Use of a selective alpha-2b-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation and method for treating or preventing an alpha-2b-adrenoceptor-mediated disease in a mammal | |
| BR0212249A (en) | Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, and use of a compound | |
| BR0212167A (en) | Oral sustained release dosage form, use thereof, method for the prevention and / or treatment of medical disorders and disorders, and process for the manufacture of an extended release dosage form | |
| DE50006842D1 (en) | 4-BENZYLAMINOCHINOLINE CONJUGATES WITH GALLIC ACID AND THEIR HETEROANALOGS, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | |
| BR0214293A (en) | A compound and methods for treating a patient having, or preventing a patient from acquiring, a disease or condition and for producing a compound or a pharmaceutically acceptable salt or ester thereof. | |
| EP1270000A3 (en) | Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7O E 8O ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009 |